Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-17 9:06 pm Purchase |
2025-03-13 | 13D | Mineralys Therapeutics, Inc. MLYS |
Samsara BioCapital, L.P. | 5,736,305 9.100% |
644,278 (+12.65%) |
Filing History |
| 2025-03-17 7:58 pm Purchase |
2025-03-13 | 13D | Mineralys Therapeutics, Inc. MLYS |
RA Capital Management, L.P. | 6,287,597 9.900% |
1,338,290 (+27.04%) |
Filing History |
| 2025-02-14 06:03 am Sale |
2024-12-31 | 13G | Mineralys Therapeutics, Inc. MLYS |
Adams Street Partners, LLC | 1,129,807 2.300% |
-1,172,522 (-50.93%) |
Filing History |
| 2024-11-13 4:27 pm Sale |
2024-09-30 | 13G | Mineralys Therapeutics, Inc. MLYS |
TCG Crossover GP II, LLC | 2,470,265 5.000% |
-714,920 (-22.45%) |
Filing History |
| 2024-11-13 4:19 pm Unchanged |
2024-09-30 | 13G | Mineralys Therapeutics, Inc. MLYS |
HBM BIOVENTURES CAYMAN LTD | 2,246,332 4.500% |
0 (Unchanged) |
Filing History |
| 2024-11-13 4:09 pm Sale |
2024-09-30 | 13G | Mineralys Therapeutics, Inc. MLYS |
Catalys Pacific Fund LP | 8,681,245 17.400% |
-528,000 (-5.73%) |
Filing History |
| 2024-02-15 4:20 pm Purchase |
2024-02-12 | 13G | Mineralys Therapeutics, Inc. MLYS |
TCG Crossover GP II, LLC | 3,185,185 6.400% |
3,185,185 (New Position) |
Filing History |
| 2024-02-14 06:04 am Purchase |
2023-12-31 | 13G | Mineralys Therapeutics, Inc. MLYS |
Adams Street Partners, LLC | 2,302,329 5.600% |
2,302,329 (New Position) |
Filing History |
| 2024-02-13 4:12 pm Purchase |
2023-12-31 | 13G | Mineralys Therapeutics, Inc. MLYS |
Catalys Pacific Fund LP | 9,209,245 22.400% |
9,209,245 (New Position) |
Filing History |
| 2024-02-13 4:09 pm Purchase |
2023-12-31 | 13G | Mineralys Therapeutics, Inc. MLYS |
HBM BIOVENTURES CAYMAN LTD | 2,246,332 5.500% |
2,246,332 (New Position) |
Filing History |
| 2024-02-12 4:49 pm Purchase |
2024-02-12 | 13D | Mineralys Therapeutics, Inc. MLYS |
RA Capital Management, L.P. | 4,949,307 9.990% |
1,768,387 (+55.59%) |
Filing History |
| 2024-02-12 4:48 pm Purchase |
2024-02-12 | 13D | Mineralys Therapeutics, Inc. MLYS |
Samsara BioCapital, L.P. | 5,092,027 10.300% |
5,092,027 (New Position) |
Filing History |
| 2023-02-24 4:30 pm Purchase |
2023-02-14 | 13D | Mineralys Therapeutics, Inc. MLYS |
RA Capital Management, L.P. | 3,180,920 7.800% |
3,180,920 (New Position) |
Filing History |
| 2023-02-24 4:01 pm Purchase |
2023-02-14 | 13G | Mineralys Therapeutics, Inc. MLYS |
Andera Partners | 2,865,976 7.000% |
2,865,976 (New Position) |
Filing History |
| 2023-02-24 4:00 pm Purchase |
2023-02-14 | 13D | COMPASS Pathways plc CMPS |
Samsara BioCapital, L.P. | 4,521,805 11.100% |
4,521,805 (New Position) |
Filing History |